Taysha Gene Therapies (TSHA) Misses Q3 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.79 million versus the consensus estimate of $1.74 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• 51Talk Online Education Group (COE) Reports Q1 EPS of $0.00
• Frequency Electronics secures $10 million credit facility with JPMorgan